Proinflammatory cytokines, tryptophan catabolites, and the gut-brain axis may have key roles in chronic fatigue and depression in patients with multiple sclerosis.
In early Parkinson Disease, fatigue, excessive daytime sleepiness, and emotional apathy are predictive of increasing fatigue severity.
Increases in multiple neurologic factors likely led the increase in United States epilepsy-related mortality rates between 1999 and 2017.
In a global, phase 3 trial, researchers evaluated the efficacy of ganaxolone as an adjunctive treatment compared to placebo for major motor seizures in patients with CDKL5 deficiency disorder.
Study findings present 71% of patients with new-onset super refractory status epilepticus as having good or fair outcomes at long-term follow-up.
Investigators conducted a survey to assess the incidence of COVID-19 in patients with multiple sclerosis as well as the influence of their comorbidities and treatments on outcomes.